Industry Trends

Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials

By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore.  Read More



Virtify’s Content-Centric Solutions Build Efficiency by Repurposing Data



By Ann Neuer

August 24, 2009 | Smart life sciences companies anxious to compress clinical development timelines are moving from a document-centric workflow to a content-centric environment. So says Stephen Bergson, executive vice president, commercial operations of Virtify, a provider of enterprise content compliance solutions.

Stephen_Bergson
Stephen Bergson
“The industry is realizing that document management systems produce static documents that are cumbersome and don’t allow for ready re-use. By moving to a content management environment, you can use, re-use and repurpose compliant content across the enterprise instead of developing the same information over and over again,” Bergson explains.

He is referring to the trend that along the continuum—from discovery to clinical trials to post-approval commercialization—sponsors are seeking to leverage content by intelligently tagging it and simply lifting it from a central data repository that is created throughout a product’s lifecycle. With that capability, data only has to be developed once and it can be re-used for any number of upstream and downstream purposes. For example, existing information can flow into structured product labeling (SPL) documents, electronic common technical documents (eCTD), and be extrapolated for manufacturing standard operating procedures (SOPs). In addition, if documents have changed since originally created, the user is notified of those changes, and only the latest versions are applied.

Being able to leverage content across the enterprise has real ramifications for speeding product development and cutting costs associated with pre- and post-marketing regulatory submissions. Research suggests that approximately 26% of the cost of bringing new drugs to market is linked to creating content in a compliant manner, so any effort to reduce that percentage will have a positive impact on the bottom line. Bergson remarks, “We believe that with effective re-use of compliant content, we can drop that figure by an order of magnitude.”

Mandates from various regulatory agencies across the globe and greater acceptance of standards are driving the move to compliant content-centric systems. Bergson points to factors such as Health Level 7 (HL7) standards, the Information Technology Plan in the Prescription Drug User Fee Act IV (PDUFA), and the European Medicines Agency’s (EMEA) mandatory use of the eCTD for submissions using the Centralised Procedure, starting January 2010. In addition, required adverse event reporting begins in September 2009, as stated in Section 801(a) of the Food and Drug Administration Amendments Act (FDAAA); and there is the upcoming regulated product submission standard.

To address this complex regulatory environment and to streamline re-use of content, Virtify recently launched Virtx, a Web-based, collaborative enterprise content compliance suite that the company claims is the industry’s first. Virtx offers end-to-end solutions through a series of modules that are out-of-the-box ready, but are also configurable. The Virtx modules include SPL, eCTD, Clinical Trial Disclosure System (CTDS), Upcoming Standards Support, and enterprise eCompliance products that automate collaborative document authoring, submissions tracking, and other functions. The suite has an extensible markup language (XML) backbone, uses Web 2.0 architecture and offers a user-friendly interface that is presented in a familiar Microsoft Word-like format.

With the September 27 start date for FDA’s required adverse event reporting on www.clinicaltrials.gov, and with the anticipation that other regulatory agencies will require this same function, there is particular interest in the Clinical Trial Disclosure System module. “CTDS is hot right now with all of the clinical trial mandates and directives coming from regulators,” Bergson comments.

Repurposing content takes the market in a promising direction. According to Bergson, “Clients are realizing that it is costing them a fortune to develop documents and then have them go into a static environment. With life science mandates extending out to 2015, and with new mandates being developed, transitioning out of a static-document world into a content-centric world is where the industry is going.”

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Life Science Webcasts & Podcasts

medidata_podcast_Sites and Sponsors: Mending Bridges over Troubled Waters  
Sites and Sponsors: Mending Bridges over Troubled Waters
Sponsored by Medidata Solutions Worldwide

This podcast brings together two industry leaders to focus on the issues that divide sponsors and sites. On the one hand sites and sponsors unite in advancing better health care through a common passion for developing better drugs. Yet some issues divide them and bridges need to be built or mended to advance the highest levels of cooperation, coordination and success in clinical trials. Listen as the key issues are debated from the site and the sponsor side and new methods and technology are advanced that offer near-term and lasting solutions.

• Common ground in reaching agreement on a budget

• Improving the pace of agreement on budgets and contracts

• Processes for payment to sites on a timely basis

Listen Now 

More Podcasts

Job Openings

Firmenich
PhD COMPUTATIONAL SYSTEMS SCIENTIST
To review full job description please go to www.Firmenich.com and search for Computational Biologist. All qualified candidates send updated resume to ppapiccio@agile1.com.
read more
abbott labs
Abbott Labs, Health Informatics Program ManagerQualified candidates may apply by posting their resume to www.abbott.com/careers. Reference number: 110844BR.
read more




For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .